VK2809

VK2809 is a novel, orally available small molecule that acts as a selective agonist of the thyroid hormone receptor beta (TRβ), with high selectivity for liver tissue. It is designed to target metabolic disorders by modulating lipid metabolism and reducing liver fat content. The drug is being developed primarily for the treatment of non-alcoholic steatohepatitis (NASH) and other lipid disorders such as hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD). VK2809 functions as a prodrug that is selectively activated in the liver by cytochrome P450 enzymes to release its active metabolite, which then binds TRβ receptors. This selectivity aims to maximize therapeutic effects in the liver while minimizing off-target effects elsewhere in the body. Clinical trials have shown significant reductions in LDL cholesterol and hepatic fat content with favorable safety and tolerability profiles[1][2][4][5][6][8].

Other names

MB-07811MB07811MB 07811